Alev Atasever

Do the Benefits Gained Using a Short-Term Pulmonary Rehabilitation Program Remain in COPD Patients After Participation?

The aim of this study was to evaluate the short-term benefits of a pulmonary rehabilitation program in chronic obstructive pulmonary disease (COPD) patients. The study was a randomized controlled trial that included 54 mild and moderate COPD patients. Patients were assigned to either an 8-week-long pulmonary rehabilitation program, which consisted of exercise plus education (rehabilitation group), or were controls. All the patients were evaluated at baseline at the completion of the 8th week of the program and one month after the completion of the pulmonary rehabilitation program using five instruments: arterial blood gas analysis, postbronchodilator pulmonary function test, 6-minute walk test (6MWT), Saint George Respiratory Questionnaire (SGRQ), and the dyspnea visual analog scale (VAS) There were no statistically significant differences in the pulmonary functions and pulmonary gas analysis between baseline, discharge (8th week), and the 12th-week visit in both groups (p > 0.05). Rehabilitation resulted in significant improvements in both the VAS and the 6MWT at the 8th week, but by the 12th week all of these improvements had deteriorated. All of the SGRQ domains improved both at the 8th and the 12th week, with a significant difference between the groups (p < 0.05). We conclude that rehabilitation resulted in improvements in exercise capacity, health status, and dyspnea. All of these benefits, however, tend to deteriorate in the first month after rehabilitation. Therefore, it is strongly recommended that all patients with COPD be kept motivated in order to continue with rehabilitation and maintain the benefits gained.

Plasma and Bronchoalveolar Lavage Fluid Levels of Endothelin-1 in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension

Background: Secondary pulmonary hypertension (PH) and cor pulmonale are the major clinical cardiovascular complications affecting prognosis in patients with chronic obstructive pulmonary disease (COPD). It is also known that endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by the pulmonary vascular endothelium, and ET-1 may be implicated in the pathogenesis of PH. Objectives: The purpose of this study was to investigate the presence of ET-1 in patients with COPD and to assess the correlation of ET-1 levels in the plasma and bronchoalveolar lavage (BAL) fluid (BALF) in COPD patients with or without PH. Methods: Twenty-two patients with COPD and 15 healthy controls were enrolled in the study. Peripheral venous blood samples were collected in all patients and controls. BAL was obtained in COPD patients, and ET-1 levels were measured by radioimmunoassay in all plasma and BALF samples. Results: Plasma ET-1 levels were 2.46 ± 0.55 and 1.70 ± 0.42 pmol/dl in patients with COPD and controls, respectively (p < 0.0001). Sixteen of the 22 patients with COPD (73%) had PH established by echocardiography. The ET-1 level in these patients amounted to 2.59 ± 0.50 pmol/dl, and it was 2.10 ± 0.54 pmol/dl in 6 patients with COPD without PH. In COPD patients with and without PH, BALF ET-1 levels were 0.19 ± 0.08 and 0.24 ± 0.01 pmol/dl, respectively (p > 0.05). Conclusions: These results suggest that ET-1 is detectable in both the peripheral blood and BALF of COPD patients, but the levels do not statistically differ between patients with and without PH.

The efficacy of incentive spirometry in patients with COPD

Objective:  Although incentive spirometry (IS) is frequently used to prevent postoperative pulmonary complications, its efficacy in patients with COPD has not been documented. The aim of this study was to evaluate the effects of IS on pulmonary function tests, arterial blood gases, dyspnoea and health‐related quality of life in patients hospitalized for COPD.

Technetium-99m-DTPA aerosol scintigraphy in amiodarone induced pulmonary toxicity in comparison with Ga-67 scintigraphy

Amiodarone hydrochloride, which is used in life-threatening cardiac tachyarrhythmia, has been known to cause amiodarone induced pulmonary toxicity (AIPT) as a complication. In this study we aimed to investigate the clinical value of technetium-99m diethylene triamine penta-acetic acid (DTPA) aerosol lung scintigraphy in patients with AIPT in comparison with gallium-67 (Ga-67) scan. The study group included 26 cases, 7 patients with diagnosis of AIPT (Group A), 8 patients receiving amiodarone therapy but without AIPT (Group B) and 11 healthy subjects as a control group (Group C). All patients underwent Ga-67 and Tc-99m-DTPA aerosol scintigraphy in addition to various laboratory tests, Ga-67 scintigraphy was positive in 4 of 7 AIPT patients but quite normal in Group B. A positive correlation was found (r=0.52, p<0.05) between kep values determined by Tc-99m-DTPA aerosol scintigraphy and the cumulative dose of amiodarone. The mean kep values were 2.04%±0.85% min, 1.30%±0.42% min and 0.86%±0.19% min for groups A, B and C, respectively. The mean clearance rate of group A was significantly faster than that of normals (p<0.0005) and group B (p=0.028). In addition, there was a significant difference between groups B and C (p=0.015).In conclusion, Ga-67 lung scintigraphy is a useful method for the detection of AIPT but Tc-99m-DTPA aerosol scintigraphy offers better results than Ga-67 scintigraphy. Early changes in Tc-99m-DTPA clearance may be observed in patients receiving amiodarone. The kep value in patients with AIPT is noticeably increased with respect to the control group. With its favorable physical properties, low cost, lower radiation burden and its ability to be used as an objective measure for the pulmonary clearance rate, Tc-99m-DTPA aerosol scintigraphy appears to be promising in patients receiving amiodarone therapy.